Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6393365 | 0.88 | MEN1 (0.64) | EPHX2FPR2TDP1HPGDLMNA | |
| SCHEMBL147824 | 0.86 | KDM4E (0.62) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4023715 | 0.83 | CA1 (0.67) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL6376510 | 0.83 | CA1 (0.67) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL8802829 | 0.82 | CA12 (0.75) | LTA4HEPHX2TP53CA1CA2 | |
| SCHEMBL8558286 | 0.80 | LMNA (0.59) | LTA4HEPHX2CA1CA2CA12 | |
| SCHEMBL6320205 | 0.78 | POLB (0.74) | EPHX2ALDH1A1FPR2HPGDLMNA | |
| SCHEMBL8803541 | 0.77 | LTA4H (0.79) | LTA4HEPHX2CA1CA2CA12 | |
| SCHEMBL4028224 | 0.77 | CA1 (0.70) | EPHX2CA1CA2ALDH1A1MAPT | |
| SCHEMBL21346450 | 0.76 | CA1 (0.69) | LTA4HEPHX2CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | LTA4H 484/4885EPHX2 1216/4885TP53 4874/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | LTA4H 247/4885EPHX2 860/4885TP53 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.